事件：2025 年3 月25 日，宜明昂科发布2024 年度业绩报告，全年实现总收入7,415 万元（主要来自授权许可费和合作开发收入），同比增长192 倍。经营活动净现金流出1.28 亿元，同比下降65%，现金及短期金融资产7.52 亿元，同比增长23%。核心资产替达派西普两项III 期临床稳步推进公司核心管线替达派西普（IMM01）联合阿扎胞苷治疗初治CMML患者的III 期临床于2024 年...
Source Link事件：2025 年3 月25 日，宜明昂科发布2024 年度业绩报告，全年实现总收入7,415 万元（主要来自授权许可费和合作开发收入），同比增长192 倍。经营活动净现金流出1.28 亿元，同比下降65%，现金及短期金融资产7.52 亿元，同比增长23%。核心资产替达派西普两项III 期临床稳步推进公司核心管线替达派西普（IMM01）联合阿扎胞苷治疗初治CMML患者的III 期临床于2024 年...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.